KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Operating Margin (2019 - 2025)

Historic Operating Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 11.41%.

  • Esperion Therapeutics' Operating Margin rose 196300.0% to 11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.67%, marking a year-over-year decrease of 152400.0%. This contributed to the annual value of 16.37% for FY2024, which is 1500900.0% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Operating Margin stood at 11.41%, which was up 196300.0% from 8.61% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Operating Margin registered a high of 52.47% during Q1 2024, and its lowest value of 1038.15% during Q1 2021.
  • Moreover, its 5-year median value for Operating Margin was 131.37% (2023), whereas its average is 178.52%.
  • Per our database at Business Quant, Esperion Therapeutics' Operating Margin skyrocketed by 30078200bps in 2021 and then plummeted by -1979800bps in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Operating Margin stood at 361.2% in 2021, then skyrocketed by 37bps to 225.92% in 2022, then soared by 42bps to 131.37% in 2023, then surged by 95bps to 6.4% in 2024, then tumbled by -78bps to 11.41% in 2025.
  • Its Operating Margin was 11.41% in Q3 2025, compared to 8.61% in Q2 2025 and 34.0% in Q1 2025.